Filing Flows › Pulmonx (LUNG) › Q3 2026 › vs Q2 2026
Pulmonx (LUNG) Q3 2026 vs Q2 2026 (quarter over quarter)
Pulmonx's revenue rose $79K (+0.3%) from $22.8M in Q2 2026 to $22.8M in Q3 2026.
Pulmonx, Q3 2026: revenue $22.8M (+6% year over year), operating margin -32.8%, net loss $8.4M, operating cash flow −$3.2M. The chart draws each line against Q2 2026, the increases inside each band.
Every line
| Line | Q3 2026 | Q2 2026 | Change | % |
|---|---|---|---|---|
| Revenue | $22.8M | $22.8M | $79K | +0.3% |
| Net loss | $8.4M | $10.1M | −$1.7M | -17% |
| Costs & expenses | $31.2M | $32.8M | −$1.6M | -5% |
| Operating costs | $30.3M | $31.8M | −$1.5M | -5% |
| Interest & other, net | $753K | $890K | −$137K | -15% |
| Income tax | $151K | $133K | $18K | +14% |
| Cost of revenue | $5.4M | $5.0M | $422K | +8% |
| Research & development | $4.9M | $5.0M | −$170K | -3% |
| SG&A | $20.0M | $21.8M | −$1.7M | -8% |
| Operating cash sources | $8.4M | $10.1M | −$1.7M | -17% |
| Depreciation | $200K | $200K | $0 | 0% |
| Share-based compensation | $3.6M | $3.7M | −$87K | -2% |
| Working capital & other | $1.4M | $968K | $432K | +45% |
| Cash used in operations | $3.2M | $5.2M | −$2.0M | -39% |
| Net loss absorbed | $8.4M | $10.1M | −$1.7M | -17% |
Questions
How much did Pulmonx's revenue grow quarter over quarter in Q3 2026?
Pulmonx's revenue rose $79K (+0.3%) from $22.8M in Q2 2026 to $22.8M in Q3 2026.